Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris

Circulation

Volumn 94, Issue 9, 1996, Pages 2057-2063

  Juhan Vague, Irène ^a   Pyke, Stephen D M ^b   Alessi, Marie Christine ^a   Jespersen, Jorgen ^c   Haverkate, Frits ^d   Thompson, Simon G ^b  

^a TIMONE HOSPITAL   (France)

^b Royal London Medical School   (United Kingdom)

^c Centralsygehuset   (Denmark)

^d TNO   (Netherlands)

Author keywords

angina; fibrinolysis; myocardial infarction; plasminogen activators; risk factors

Indexed keywords

ANGINA PECTORIS; ARTICLE; CORONARY ARTERY THROMBOSIS; CORONARY RISK; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH;

EID: 0029805074     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2057     Document Type: Article

References (56)

1. Zack PM, Ischinger T, Aker UT, Dincer B, Kennedy HL. The occurrence of angiographically detected intracoronary thrombus in patients with unstable angina pectoris. Am Heart J. 1984;108: 1408-1412.
2. De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
3. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310: 1137-1140.
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:210-218,242-250.
5. Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor 1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost. 1992;68:60-63.
6. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusion in mice transgenic for the plasminogen activator inhibitor 1 gene. Nature, 1990:346:74-76.
7. Pedersen OD, Gram J, Jespersen J. Plasminogen activator inhibitor type 1 determines plasmin formation in patients with ischemic heart disease. Thromb Haemost. 1995;73:835-840.
8. Nicoloso G, Hauert J, Kruithof EKO, van Melle G, Bachmann F. Fibrinolysis in normal subjects: comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemost. 1988;59:299-303.
9. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor 1 in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis. 1989;9:362-367.
10. Alessi MC, Juhan-Vague I, Declerck PJ, Anfosso F, Gueunoun E, Collen D. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thromb Res. 1990;60:509-516.
11. Meade TW, Howarth DJ, Cooper J, MacCallum PK, Stirling Y. Fibrinolytic activity and arterial disease. Lancet. 1994;343:1442. Letter.
12. Ranby M, N'Guyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Thromb Haemost. 1989;61:409-414.
13. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor-1 and atherothrombosis. Thromb Haemost. 1993;70:138-143.
14. Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342: 1076-1079.
15. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991;12:157-161.
16. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation. 1993;88:2030-2034.
17. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
18. van de Loo JCW, Haverkate F, Thompson SG. Hemostatic factors and the risk of myocardial infarction. N Engl J Med. 1995:332:389-390. Letter.
19. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue type plasminogen activator and risk of myocardial! infarction. Lancet. 1193;341:1165-1168.
20. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
21. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B, Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
22. Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial infarction. Acta Med Scand. 1987;221:149-153.
23. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Speechia G, Tarazzi L, Tremoli E, Pozzili E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb. 1993;13:1412-1417.
24. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Med J. 1991;66:351-355.
25. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
26. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb. 1993;13: 1865-1873.
27. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993;42:945-949.
28. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type 1 : implications for vascular disease by hyperinsulmemic states. Proc Natl Acad Sci U S A. 1991;88:9959-9963.
29. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988:37:1595-1607.
30. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-422.
31. Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris: relation to gender, age and acute-phase reaction. Thromb Haemost. 1995;73:561-567.
32. Thompson SG, Duckert F, Haverkate F, Thomson JM. The measurement of haemostatic factors in 16 European laboratories: quality assessment for the multicentre ECAT Angina Pectoris Study. Thromb Haemost. 1989;1:301-306.
33. Jespersen J, Bertina RM, Haverkate F, eds. In: ECAT Assay Procedures: A Manual of Laboratory Techniques. Dordrecht, Netherlands: Kluwer Academic Press; 1992.
34. ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 1993;14:8-17.
35. Thompson SG, Calori G, Thomson JM, Haverkate F, Duckert F. The impact of sequential quality assessment exercises on laboratory performance: the multicentre ECAT Angina Pectoris Study. Thromb Haemost. 1991;65:149-152.
36. CASS Principal Investigators and Their Associates. Myocardial infarction and mortality in the Coronary Artery Surgery Study (CASS) randomized trial. N Engl J Med. 1984;310:750-758.
37. Blann AD. Von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci. 1993;50:125-134.
38. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
39. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
40. Meade TW, Cooper SA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ, Factor VIII, ABO blood group and the incidence of ischemic heart disease. Br J Haemost. 1994;88:601-607.
41. Sundell IB, Nilsson TK, Hallmans G, Hellsten G, Dahlen GH. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. Atherosclerosis. 1989;80:9-16.
42. Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A, Relationships between euglobulin clot lysis time and the plasma level of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost. 1990;63:82-86.
43. Iso H, Folsom AR, Koike KA, Sato S, Wu KK, Shimamoto T, Iida M, Komachi Y. Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: correlates in non smoking Japanese and Caucasian men and women. Thromb Haemost. 1993;70:475-480.
44. Rijken DC, Juhan-Vague I, Collen D. Complexes between extrinsic plasminogen activator and proteinase inhibitors in human plasma identified with an immunoradiometric assay. J Lab Clin Med. 1983;101:285-294.
45. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody based enzyme linked immunosorbent assay. Blood. 1988;71:220-225.
46. Juhan-Vague I, Alessi MC, Fossat C, Declerck PJ, Kruithof EKO. Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture. Thromb Haemost. 1987;58:1096. Letter.
47. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in pfasma and platelets. Br J Haematol. 1988;70:327-333.
48. Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood or tissue-type plasminogen activator (t-PA) and its fast acting inhibitor PAI-1. Thromb Haemost. 1988;59:329-332.
49. Juhan-Vague I, Alessi MC, Raccah D, Aillaud MF, Billerey M, Ansaldi J, Philip-Joet C, Vague P. Daytime fluctuations of plasminogen activator inhibitor (PAI-1) in populations with high PAI-1 levels. Thromb Haemost. 1992;67:76-82.
50. Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. In: Lijnen HR, Collen D, eds. Baillieres Clin Haematol. 1995;8:277-290.
51. Bosma PJ, van den Berg EA, Kooistra T. Human plasminogen activator inhibitor 1 gene: promoter and structural gene nucleotide sequences. J Biol Chem. 1988;263:9129-9141.
52. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAM complex in plasma. Blood. 1990;76:930-937.
53. Brommer EJP, Derkx FHM, Schalekamp MADH, Dooijewaard G, Klaauw MM. Renal and hepatic handling of endogenous tissue-type plasminogen activator and its inhibitor in man. Thromb Haemost. 1988;59:404-411.
54. Jansson JH, Norberg B, Nilsson TK. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. Clin Chem. 1989;35:1544-1550.
55. Nguyen ND, Ghaddar H, Stinson V, Chambless LE, Wu KK. ARIC hemostasis study: intraindividual variability and reliability of hemostatic factors. Thromb Haemost, 1995;73:256-260.
56. Nilsson TK, Boman K, Bjerle P, Hallmans G, Hellsten G. Von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med. 1994;235:419-423.